Science

Thu, 28/09/2017 - 08:30
London, UK, 28th September 2017 / Sciad Newswire / The US approval of Novartis's  Kymriah for childhood leukaemia opens a dramatic new era of cancer therapy deplo
Wed, 20/09/2017 - 07:30
Edinburgh, UK, 20th September 2017 / Sciad Newswire / Synpromics Ltd, the leader in gene control, today announces a new r
Mon, 18/09/2017 - 07:30
Cambridge, UK, 18th September 2017 / Sciad Newswire / Cypralis, a life sciences company focused on the discovery of therape
Wed, 30/08/2017 - 15:30
London, UK, 25th August 2017 / Sciad Newswire / Touchlight Genetics Ltd has developed a revolutionary DNA technology that can synthetically manufacture commercial
Wed, 12/07/2017 - 12:23
London, UK, 12th July 2017 / Sciad Newswire / SynbiCITE and Rainbow Seed Fund co
Thu, 29/06/2017 - 07:30
Australian immuno-oncology company Minomic International Ltd is proceeding to the second stage of its pioneering MILGa clinical trial of MiltuximabTM, a chimeric version of Minomic’s MIL-38 anti-Glypican1 antibody conjugated to the radioactive isotope 67Gallium.
Mon, 12/06/2017 - 07:30
Coventry, UK, 12th June 2017 / Sciad Newswire / Medherant Ltd, a University of Warwick spin-out company developing a nov
Wed, 24/05/2017 - 07:30
Epsom, UK, 24th May 2017 / Sciad Newswire / While many industries will benefit from the remarkable properties of graphene, three stand out as having the greatest
Thu, 06/04/2017 - 17:00
Munich, Germany, 6th April 2017 / Sciad Newswire / Max Planck scientists unravel when during development the 3

Pages